|
1
|
Blot WJ and McLaughlin JK: The changing
epidemiology of esophageal cancer. Semin Oncol. 26:2–8.
1999.PubMed/NCBI
|
|
2
|
American Cancer Society. Cancer facts and
figures, 2005. Atlanta, GA: American Cancer Society; 2005
|
|
3
|
Zou XN, Chen WQ, Zhang SW, Li LD, Lu FZ
and Chen YH: An analysis of esophageal cancer incidence and
mortality from 30 cancer registries in China, 1998–2002. Chin
Cancer. 161:142–146. 2007.
|
|
4
|
Stoner GD and Gupta A: Etiology and
chemoprevention of esophageal squamous cell carcinoma.
Carcinogenesis. 22:1737–1746. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kakizoe T: Chemoprevention of cancer -
focusing on clinical trials. Jpn J Clin Oncol. 33:421–442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cragg GM, Grothaus PG and Newman DJ:
Impact of natural products on developing new anti-cancer agents.
Chem Rev. 109:3012–3043. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koehn FE and Carter GT: The evolving role
of natural products in drug discovery. Nat Rev Drug Discov.
4:206–220. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mann J: Natural products in cancer
chemotherapy: past, present and future. Nat Rev Cancer. 2:143–148.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
National Committee of Pharmacopoeia.
Pharmacopoeia of the People’s Republic of China. Chemical Industry
Publishing Company; Beijing, China: pp. 1812005, (In Chinese).
|
|
10
|
Itokawa H, Xu JP and Takeya K: Studies on
chemical constituents of antitumor fraction from Periploca
sepium. V Structures of new pregnane glycosides, periplocosides
J, K, F and O. Chem Pharm Bull. 36:4441–4446. 1998.PubMed/NCBI
|
|
11
|
Zhang J, Shan BE and Liu GS: Apoptosis
induced by ethyl acetate extract from Cortex periplocae in
human breast cancer cell line MCF-7. Tumor. 26:418–421. 2006.(in
Chinese).
|
|
12
|
Zhao LM, Shan BE, Ai J, Ren FZ and Lian
YS: Effects of periplocin from Cortex periplocae on
proliferation of human esophageal carcinoma cells TE-13 and related
mechanisms. Tumor. 28:203–206. 2008.(in Chinese).
|
|
13
|
Polakis P: The oncogenic activation of
beta-catenin. Curr Opin Genet Dev. 9:15–21. 1999. View Article : Google Scholar
|
|
14
|
Waltzer L and Bienz M: The control of
beta-catenin and TCF during embryonic development and cancer.
Cancer Metastasis Rev. 18:231–246. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Behrens J: Control of beta-catenin
signaling in tumor development. Ann NY Acad Sci. 910:21–33. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lv J, Cao XF, Ji L, Zhu B, Tao L and Wang
DD: Association of Wnt1/beta-catenin with clinical pathological
characteristics and prognosis of esophageal squamous cell
carcinoma. Genet Test Mol Biomarkers. 14:363–369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Luu HH, Zhang R, Haydon RC, Rayburn E,
Kang Q, Si W, Park K, Wang H, Peng Y, Jiang W and He TC:
Wnt/beta-catenin signaling pathway as a novel cancer drug target.
Curr Cancer Drug Targets. 4:653–671. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kitagawa M, Hatakeyama S, Shirane M,
Matsumoto M, Ishida N, Hattori K, Nakamichi I, Kikuchi A and
Nakayama K: An F-box protein, FWD1, mediates ubiquitin-dependent
proteolysis of beta-catenin. EMBO J. 18:2401–2410. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu C, Li Y, Semenov M, Han C, Baeg GH,
Tan Y, Zhang Z, Lin X and He X: Control of beta-catenin
phosphorylation/degradation by a dual-kinase mechanism. Cell.
108:837–847. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nelson WJ and Nusse R: Convergence of Wnt,
beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moon RT, Bowerman B, Boutros M and
Perrimon N: The promise and perils of Wnt signaling through
beta-catenin. Science. 296:1644–1646. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Akiyama T: Wnt/beta-catenin signaling.
Cytokine Growth Factor Rev. 11:273–282. 2000. View Article : Google Scholar
|
|
23
|
Takahashi-Yanaga F and Sasaguri T: Drug
development targeting the glycogen synthase kinase-3beta
(GSK-3beta)-mediated signal transduction pathway: inhibitors of the
Wnt/beta-catenin signaling pathway as novel anticancer drugs. J
Pharmacol Sci. 109:179–183. 2009. View Article : Google Scholar
|
|
24
|
Xiang YY, Wang DY, Tanaka M, Igarashi H,
Kamo T, Shen Q, Sugimura H and Kino I: Efficient and specific
induction of esophageal tumors in rats by precursors of
N-nitrososarcosine ethyl ester. Pathol Int. 45:415–421. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang L, Lu A, Liu X, Sang M, Shan B, Meng
F, Cao Q and Ji X: The flavonoid Baohuoside-I inhibits cell growth
and downregulates survivin and cyclin D1 expression in esophageal
carcinoma via β-catenin-dependent signaling. Oncol Rep.
26:1149–1156. 2011.PubMed/NCBI
|
|
26
|
Osterheld MC, Bian YS, Bosman FT,
Benhatter J and Fontolliet C: Beta-catenin expression and its
association with prognostic factors in adenocarcinoma developed in
Barrett esophagus. Am J Clin Pathol. 117:451–456. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu D and Pan W: GSK3: a multifaceted
kinase in Wnt signaling. Trends Biochem Sci. 35:161–168. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He TC, Sparks AB, Rago C, Hermeking H,
Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW:
Identification of c-myc as a target of the APC pathway. Science.
281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Giles RH, van Es JH and Clevers H: Caught
up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta.
1653:1–24. 2003.PubMed/NCBI
|
|
30
|
Situ DR, Hu Y, Zhu ZH, Wang J, Long H and
Rong TH: Prognostic relevance of β-catenin expression in T2-3N0M0
esophageal squamous cell carcinoma. World J Gastroenterol.
16:5195–5202. 2010.
|
|
31
|
Yang F, Zeng Q, Yu G, Li S and Wang CY:
Wnt/beta-catenin signaling inhibits death receptor-mediated
apoptosis and promotes invasive growth of HNSCC. Cell Signal.
18:679–687. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Goto M, Mitra RS, Liu M, Lee J, Henson BS,
Carey T, Bradford C, Prince M, Wang CY, Fearon ER and D’Silva NJ:
Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent
transcription and invasion in squamous cell carcinoma of the head
and neck. Clin Cancer Res. 16:65–76. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tsai YP, Yang MH, Huang CH, Chang SY, Chen
PM, Liu CJ, Teng SC and Wu KJ: Interaction between HSP60 and
beta-catenin promotes metastasis. Carcinogenesis. 30:1049–1057.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Morin PJ, Sparks AB, Korinek V, Barker N,
Clevers H, Vogelstein B and Kinzler KW: Activation of
beta-catenin-Tcf signaling in colon cancer by mutations in
beta-catenin or APC. Science. 275:1787–1790. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dilek FH, Topak N, Tokyol C, Akbulut G and
Dilek ON: β-Catenin and its relation to VEGF and cyclin D1
expression in pT3 rectosigmoid cancers. Turk J Gastroenterol.
21:365–371. 2010.
|
|
36
|
DasGupta R, Kaykas A, Moon RT and Perrimon
N: Functional genomic analysis of the Wnt-wingless signaling
pathway. Science. 308:826–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saifo MS, Rempinski DR Jr, Rustum YM and
Azrak RG: Targeting the oncogenic protein beta-catenin to enhance
chemotherapy outcome against solid human cancers. Mol Cancer.
9:310–320. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Paul S and Dey A: Wnt signaling and cancer
development: therapeutic implication. Neoplasma. 55:165–176.
2008.PubMed/NCBI
|
|
39
|
Ma C, Wang J, Gao Y, Gao TW, Chen G, Bower
KA, Odetallah M, Ding M, Ke Z and Luo J: The role of glycogen
synthase kinase 3beta in the transformation of epidermal cells.
Cancer Res. 67:7756–7764. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang W, Xue L and Wang P: Prognostic value
of β-catenin, c-myc, and cyclin D1 expressions in patients with
esophageal squamous cell carcinoma. Med Oncol. 28:163–169.
2011.
|
|
41
|
Albihn A, Johnsen JI and Henriksson MA:
MYC in oncogenesis and as a target for cancer therapies. Adv Cancer
Res. 107:163–224. 2010. View Article : Google Scholar : PubMed/NCBI
|
